The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Phase II trial of irpagratinib and atezolizumab in FGF19+ advanced HCC
Qi Cheng, PhD, Huazhong University of Science and Technology, Wuhan, China, discusses a Phase II trial (NCT05441475) of irpagratinib and atezolizumab in FGF19+ advanced hepatocellular carcinoma (HCC). The combination showed encouraging response rates and progression-free survival in both first-line and checkpoint inhibitor-pretreated populations, including patients with prior checkpoint inhibitor exposure. The safety profile was manageable, with no grade 4/5 treatment-related adverse events or discontinuations. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The updated results from the 220 microgram BID cohort of irpagratinib in combination with atezolizumab are highly encouraging, demonstrating both robust efficacy and manageable safety. The ORR exceeded 50% in both treatment-naïve and pretreated HCC patients, surpassing the response rate of currently available therapies. The median PFS was 7 months in pretreated patients and 8...
The updated results from the 220 microgram BID cohort of irpagratinib in combination with atezolizumab are highly encouraging, demonstrating both robust efficacy and manageable safety. The ORR exceeded 50% in both treatment-naïve and pretreated HCC patients, surpassing the response rate of currently available therapies. The median PFS was 7 months in pretreated patients and 8.3 months in treatment-naïve patients, which is particularly impressive in the context of FGFR19 overexpression HCC.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
